Calithera Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-06-01
- Employees
- 10
- Market Cap
- $487
- Website
- http://www.calithera.com
Clinical Trials
30
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (29 trials with phase data)• Click on a phase to view related trials
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Non-GCB/ABC Diffuse Large B-Cell LymphomaWith and Without MyD88 and/or CD79B Mutations
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 2
- Registration Number
- NCT05319028
- Locations
- 🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸Henry Ford Health, Detroit, Michigan, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
- Conditions
- NFE2L2 Gene MutationSquamous Non-Small Cell Neoplasm of LungNon-Small Cell Lung CancerSquamous Non-small-cell Lung Cancer
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Faeth Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT05275673
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Davis, California, United States
🇺🇸Providence Medical Group Santa Rosa - Cancer Center, Santa Rosa, California, United States
🇺🇸Florida Cancer Specialists, Tallahassee, Florida, United States
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
- Conditions
- Non-Small Cell Lung CancerNFE2L2 Gene MutationKEAP1 Gene MutationNRF2 MutationNon-Squamous Non-Small Cell Neoplasm of LungNon-squamous Non-small-cell Lung Cancer
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT04698681
- Locations
- 🇺🇸
Southern Cancer Center, Daphne, Alabama, United States
🇺🇸Southern Cancer Center - 3 Mobile Infirmary Circle, Mobile, Alabama, United States
🇺🇸Southern Cancer Center - Dauphin St, Mobile, Alabama, United States
Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects
- Conditions
- Cardiac Safety
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT04607512
- Locations
- 🇬🇧
Celerion, Belfast, Ireland, United Kingdom
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
- Conditions
- Drug Interaction
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 22
- Registration Number
- NCT04540965
- Locations
- 🇦🇺
Nucleus Network Brisbane Clinic (formerly Q-Pharm), Brisbane, Queensland, Australia
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next